Diabetic Macular Edema (DME) is a major complication of diabetic retinopathy characterized by fluid accumulation in the macula, leading to vision impairment. The standard treatment involves anti-VEGF (Vascular Endothelial Growth Factor) therapy, but ...
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Dec 18, 2024
Therapeutic proteins, the fastest growing class of pharmaceuticals, are subject to rapid proteolytic degradation in vivo, rendering them inactive. Sophisticated drug delivery systems that maintain protein stability, prolong therapeutic effects, and r...
BACKGROUND: Investigate retinal fluid changes via a novel deep-learning algorithm in real-world patients receiving faricimab for the treatment of neovascular age-related macular degeneration (nAMD).
Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
Dec 2, 2024
This genetic association study including 120 patients with type 2 diabetes mellitus (T2DM) and 166 non-diabetic individuals aimed to investigate the association of polymorphisms in the genes GSTM1 and GSTT1 (gene deletion), GSTP1 (rs1695), ACE (rs464...
Age-related macular degeneration is a retinal disease that severely impacts vision in the older population. Its gene-related heterogeneity has not been fully studied, increasing the burden of precise treatment, prevention and prognosis. Genetic varia...
Age-related macular degeneration (AMD) is a major cause of blindness in developed countries, and the number of affected patients is increasing worldwide. Intravitreal injections of anti-vascular endothelial growth factor (VEGF) are the standard thera...
BACKGROUND/OBJECTIVES: To characterise morphological changes in neovascular age-related macular degeneration (nAMD) during anti-angiogenic therapy and explore relationships with best-corrected visual acuity (BCVA) and development of macular atrophy (...
AIM: To predict antivascular endothelial growth factor (VEGF) treatment requirements, visual acuity and morphological outcomes in neovascular age-related macular degeneration (nAMD) using fluid quantification by artificial intelligence (AI) in a real...
BACKGROUND/OBJECTIVES: Anti-VEGF treatment response in DMO has been measured by changes in the central subfield thickness (CST) and best visual acuity (BVA) outcomes at 3 months after initial treatment, termed early or limited early response (ER/LER)...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.